Director Program Management 1 and 1 Full Life Cycle
Monte Rosa Therapeutics
Director Program Management 1 and 1 Full Life Cycle
Monte Rosa Therapeutics
Develops targeted protein degraders for therapy
The Associate Director of Program Management will serve as a strategic and operational leader for priority immunology and inflammation programs, driving assets from mid- to late-stage development through regulatory submission. This role is designed for a hands-on, agile leader who thrives in a fast-paced biotechnology environment and can rapidly translate evolving science into executable development strategy.
As a core member of the Program Team, the Director will partner closely with Clinical, Regulatory, CMC, Nonclinical, Biomarkers, Translational Sciences, and Commercial leaders to integrate strategy and execution across the full development lifecycle. This individual will ensure alignment to the Target Product Profile (TPP) and Integrated Development Plan (IDP), while enabling flexibility as data emerge and scientific understanding evolves.
Success in this role requires deep familiarity with immunology and inflammation drug development, comfort operating amid uncertainty, and the ability to balance scientific rigor with speed, capital efficiency, and enterprise priorities.
• 12+ years of experience in biotechnology or pharmaceutical drug development.• Minimum 8 years of program/project management experience leading cross-functional development teams.• Demonstrated experience advancing immunology and/or inflammation assets through Phase 2 and Phase 3 development.• Experience preparing for and supporting major regulatory interactions (e.g., End-of-Phase 2 meetings, NDA/BLA submissions).• Experience operating in small-to-mid-sized biotech environments where agility and hands-on leadership are required.
Education
• BS required; advanced degree (MS, PhD, or MBA) strongly preferred.• PMP certification desirable but not required.
Technical & Leadership Capabilities
• Strong understanding of immunology and inflammation biology, clinical endpoints, biomarker strategy, and regulatory considerations.• Deep knowledge of end-to-end drug development within a resource-conscious biotech setting.• Demonstrated ability to lead through ambiguity and adapt strategy as data emerge.• Proven success influencing senior stakeholders in a highly matrixed environment.• Expertise in integrated planning, risk management, and scenario modeling.• Strong executive presence with the ability to communicate complex scientific and operational topics clearly and concisely.• Proficiency with modern project management and collaboration tools (e.g., Smartsheet, MS Project, Teams).• Exceptional organizational skills with the ability to manage multiple interdependent workstreams simultaneously.• High emotional intelligence, strong conflict resolution skills, and the ability to build trust across scientific and operational teams.• Comfort operating with urgency, limited infrastructure, and evolving priorities typical of innovative biotech companies.
Compensation: 150000 to 225000 (USD)
Develops targeted protein degraders for therapy
Monte Rosa Therapeutics develops molecular glue degraders (MGDs) to treat cancer and autoimmune/inflammatory diseases using its QuEEN discovery engine, a platform that fuses AI-guided chemistry, proteomics, and structural biology to design MGDs. MGDs work by bringing a target protein together with an E3 ligase, tagging the protein for destruction by the cell's proteasome rather than just inhibiting it. The company distinguishes itself with the QuEEN platform, partnerships with Roche and Novartis for joint development and funding, and a portfolio that includes MRT-2359, MRT-6160, and MRT-8102 as clinical-stage programs. Its goal is to discover, develop, and commercialize MGDs, grow its pipeline, and create value through collaborations, upfront payments, milestones, and royalties while delivering treatments for patients with serious diseases.
Explore more opportunities at Monte Rosa Therapeutics